Long non-coding RNA EWSAT1 promotes human nasopharyngeal carcinoma cell growth in vitro by targeting miR-326/-330-5p

Aging

Volumn 8, Issue 11, 2016, Pages 2948-2960

  Song, Peng ^a   Yin, Shu Cheng ^a  

^a ZHONGNAN HOSPITAL OF WUHAN UNIVERSITY   (China)

Author keywords

Cyclin D1; Ewing sarcoma associated transcript 1 (EWSAT1); Hsa miRNA 326 330 5p (miR 326 330 5p); Nasopharyngeal carcinoma (NPC); Tumorigenesis

Indexed keywords

CYCLIN D1; EWSR1 PROTEIN, HUMAN; MICRORNA; MIRN326 MICRORNA, HUMAN; RNA BINDING PROTEIN EWS;

CARCINOMA; CELL PROLIFERATION; GENE EXPRESSION REGULATION; GENETICS; HUMAN; METABOLISM; NASOPHARYNX TUMOR; PATHOLOGY; PHYSIOLOGY; TUMOR CELL LINE;

CARCINOMA; CELL LINE, TUMOR; CELL PROLIFERATION; CYCLIN D1; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; MICRORNAS; NASOPHARYNGEAL NEOPLASMS; RNA-BINDING PROTEIN EWS;

EID: 85001975485     PISSN: 19454589     EISSN: None     Source Type: Journal    
DOI: 10.18632/aging.101103     Document Type: Article

References (62)

1. Wei KR, Zheng RS, Zhang SW, Liang ZH, Ou ZX, Chen WQ. Nasopharyngeal carcinoma incidence and mortality in China in 2010. Chin J Cancer. 2014; 33:381-87.
2. Chen YP, Wang ZX, Chen L, Liu X, Tang LL, Mao YP, Li WF, Lin AH, Sun Y, Ma J. A Bayesian network metaanalysis comparing concurrent chemoradiotherapy followed by adjuvant chemotherapy, concurrent chemoradiotherapy alone and radiotherapy alone in patients with locoregionally advanced nasopharyngeal carcinoma. Ann Oncol. 2015; 26:205-11. doi: 10.1093/annonc/mdu507.
3. Chen YP, Wang ZX, Chen L, Liu X, Tang LL, Mao YP, Li WF, Lin AH, Sun Y, Ma J. A Bayesian network metaanalysis comparing concurrent chemoradiotherapy followed by adjuvant chemotherapy, concurrent chemoradiotherapy alone and radiotherapy alone in patients with locoregionally advanced nasopharyngeal carcinoma. Ann Oncol. 2015; 26:205-11. doi: 10.1093/annonc/mdu507.
4. Ørom UA, Derrien T, Beringer M, Gumireddy K, Gardini A, Bussotti G, Lai F, Zytnicki M, Notredame C, Huang Q, Guigo R, Shiekhattar R. Long noncoding RNAs with enhancer-like function in human cells. Cell. 2010; 143:46-58. doi: 10.1016/j.cell.2010.09.001.
5. Geisler S, Lojek L, Khalil AM, Baker KE, Coller J. Decapping of long noncoding RNAs regulates inducible genes. Mol Cell. 2012; 45:279-91. doi: 10.1016/j.molcel.2011.11.025.
6. Lin A, Li C, Xing Z, Hu Q, Liang K, Han L, Wang C, Hawke DH, Wang S, Zhang Y, Wei Y, Ma G, Park PK, et al. The LINK-A lncRNA activates normoxic HIF1a signalling in triple-negative breast cancer. Nat Cell Biol. 2016; 18:213-24. doi: 10.1038/ncb3295.
7. Marques Howarth M, Simpson D, Ngok SP, Nieves B, Chen R, Siprashvili Z, Vaka D, Breese MR, Crompton BD, Alexe G, Hawkins DS, Jacobson D, Brunner AL, et al. Long noncoding RNA EWSAT1-mediated gene repression facilitates Ewing sarcoma oncogenesis. J Clin Invest. 2014; 124:5275-90. doi: 10.1172/JCI72124.
8. Sun C, Li S, Zhang F, Xi Y, Wang L, Bi Y, Li D. Long noncoding RNA NEAT1 promotes non-small cell lung cancer progression through regulation of miR-377-3p E2F3 pathway. Oncotarget. 2016; 7:51784-814. 10.18632/oncotarget.10108. Epub ahead of print.
9. Zang C, Nie FQ, Wang Q, Sun M, Li W, He J, Zhang M, Lu KH. Long non-coding RNA LINC01133 represses KLF2, P21 and E-cadherin transcription through binding with EZH2, LSD1 in non small cell lung cancer. Oncotarget. 2016; 7:11696-707. doi: 10.18632/oncotarget.7077.
10. Khorkova O, Hsiao J, Wahlestedt C. Basic biology and therapeutic implications of lncRNA. Adv Drug Deliv Rev. 2015; 87:15-24. doi: 10.1016/j.addr.2015.05.012.
11. Yuan SX, Wang J, Yang F, Tao QF, Zhang J, Wang LL, Yang Y, Liu H, Wang ZG, Xu QG, Fan J, Liu L, Sun SH, Zhou WP. Long noncoding RNA DANCR increases stemness features of hepatocellular carcinoma by derepression of CTNNB1. Hepatology. 2016; 63:499-511. doi: 10.1002/hep.27893.
12. Wang F, Yuan JH, Wang SB, Yang F, Yuan SX, Ye C, Yang N, Zhou WP, Li WL, Li W, Sun SH. Oncofetal long noncoding RNA PVT1 promotes proliferation and stem cell-like property of hepatocellular carcinoma cells by stabilizing NOP2. Hepatology. 2014; 60:1278-90. doi: 10.1002/hep.27239.
13. Lu Z, Xiao Z, Liu F, Cui M, Li W, Yang Z, Li J, Ye L, Zhang X. Long non-coding RNA HULC promotes tumor angiogenesis in liver cancer by up-regulating sphingosine kinase 1 (SPHK1). Oncotarget. 2016; 7:241-54. doi: 10.18632/oncotarget.6280.
14. Yang QQ, Deng YF. Genome-wide analysis of long non-coding RNA in primary nasopharyngeal carcinoma by microarray. Histopathology. 2015; 66:1022-30. doi: 10.1111/his.12616.
15. Hiraki M, Nishimura J, Takahashi H, Wu X, Takahashi Y, Miyo M, Nishida N, Uemura M, Hata T, Takemasa I, Mizushima T, Soh JW, Doki Y, et al. Concurrent Targeting of KRAS and AKT by MiR-4689 Is a Novel Treatment Against Mutant KRAS Colorectal Cancer. Mol Ther Nucleic Acids. 2015; 4:e231. doi: 10.1038/mtna.2015.5.
16. Stiuso P, Potenza N, Lombardi A, Ferrandino I, Monaco A, Zappavigna S, Vanacore D, Mosca N, Castiello F, Porto S, Addeo R, Prete SD, De Vita F, et al. MicroRNA-423-5p Promotes Autophagy in Cancer Cells and Is Increased in Serum From Hepatocarcinoma Patients Treated With Sorafenib. Mol Ther Nucleic Acids. 2015; 4:e233. doi: 10.1038/mtna.2015.8.
17. Misso G, Di Martino MT, De Rosa G, Farooqi AA, Lombardi A, Campani V, Zarone MR, Gullà A, Tagliaferri P, Tassone P, Caraglia M. Mir-34: a new weapon against cancer? Mol Ther Nucleic Acids. 2014; 3:e194. doi: 10.1038/mtna.2014.47.
18. Yang C, Sun C, Liang X, Xie S, Huang J, Li D. Integrative analysis of microRNA and mRNA expression profiles in non-small-cell lung cancer. Cancer Gene Ther. 2016; 23:90-97. doi: 10.1038/cgt.2016.5.
19. Sun C, Yang C, Xue R, Li S, Zhang T, Pan L, Ma X, Wang L, Li D. Sulforaphane alleviates muscular dystrophy in mdx mice by activation of Nrf2. J Appl Physiol (1985). 2015; 118:224-37. doi: 10.1152/japplphysiol.00744.2014.
20. Sun CC, Li SJ, Yang CL, Xue RL, Xi YY, Wang L, Zhao QL, Li DJ. Sulforaphane Attenuates Muscle Inflammation in Dystrophin-deficient mdx Mice via NF-E2-related Factor 2 (Nrf2)-mediated Inhibition of NF-κB Signaling Pathway. J Biol Chem. 2015; 290:17784-95. doi: 10.1074/jbc.M115.655019.
21. Sun C, Li S, Li D. Sulforaphane mitigates muscle fibrosis in mdx mice via Nrf2-mediated inhibition of TGF-β/Smad signaling. J Appl Physiol (1985). 2016; 120:377-90. doi: 10.1152/japplphysiol.00721.2015.
22. Fang J, Sun CC, Gong C. Long noncoding RNA XIST acts as an oncogene in non-small cell lung cancer by epigenetically repressing KLF2 expression. Biochem Biophys Res Commun. 2016; 478:811-17. doi: 10.1016/j.bbrc.2016.08.030.
23. Zeng Z, Tung CH, Zu Y. A cancer cell-activatable aptamer-reporter system for one-step assay of circulating tumor cells. Mol Ther Nucleic Acids. 2014; 3:e184. doi: 10.1038/mtna.2014.36.
24. Sun H, Zhu X, Lu PY, Rosato RR, Tan W, Zu Y. Oligonucleotide aptamers: new tools for targeted cancer therapy. Mol Ther Nucleic Acids. 2014; 3:e182. doi: 10.1038/mtna.2014.32.
25. Arif T, Vasilkovsky L, Refaely Y, Konson A, Shoshan-Barmatz V. Silencing VDAC1 Expression by siRNA Inhibits Cancer Cell Proliferation and Tumor Growth In Vivo. Mol Ther Nucleic Acids. 2014; 3:e159. doi: 10.1038/mtna.2014.9.
26. Arif T, Vasilkovsky L, Refaely Y, Konson A, Shoshan-Barmatz V. Silencing VDAC1 Expression by siRNA Inhibits Cancer Cell Proliferation and Tumor Growth In Vivo. Mol Ther Nucleic Acids. 2014; 3:e159. doi: 10.1038/mtna.2014.9.
27. Chi Y, Wang X, Yang Y, Zhang C, Ertl HC, Zhou D. Survivin-targeting Artificial MicroRNAs Mediated by Adenovirus Suppress Tumor Activity in Cancer Cells and Xenograft Models. Mol Ther Nucleic Acids. 2014; 3:e208. doi: 10.1038/mtna.2014.59.
28. Sun C, Liu Z, Li S, Yang C, Xue R, Xi Y, Wang L, Wang S, He Q, Huang J, Xie S, Jiang W, Li D. Down-regulation of c-Met and Bcl2 by microRNA-206, activates apoptosis, and inhibits tumor cell proliferation, migration and colony formation. Oncotarget. 2015; 6:25533-74. doi: 10.18632/oncotarget.4575.
29. Sun C, Sang M, Li S, Sun X, Yang C, Xi Y, Wang L, Zhang F, Bi Y, Fu Y, Li D. Hsa-miR-139-5p inhibits proliferation and causes apoptosis associated with down-regulation of c-Met. Oncotarget. 2015; 6:39756-92. doi: 10.18632/oncotarget.5476.
30. Sun C, Liu Z, Li S, Yang C, Xue R, Xi Y, Wang L, Wang S, He Q, Huang J, Xie S, Jiang W, Li D. Down-regulation of c-Met and Bcl2 by microRNA-206, activates apoptosis, and inhibits tumor cell proliferation, migration and colony formation. Oncotarget. 2015; 6:25533-74. doi: 10.18632/oncotarget.4575.
31. Sun CC, Li SJ, Li DJ. Hsa-miR-134 suppresses non-small cell lung cancer (NSCLC) development through downregulation of CCND1. Oncotarget. 2016; 7:35960-78.
32. Sun C, Sang M, Li S, Sun X, Yang C, Xi Y, Wang L, Zhang F, Bi Y, Fu Y, Li D. Hsa-miR-139-5p inhibits proliferation and causes apoptosis associated with down-regulation of c-Met. Oncotarget. 2015; 6:39756-92. doi: 10.18632/oncotarget.5476.
33. Sun C, Huang C, Li S, Yang C, Xi Y, Wang L, Zhang F, Fu Y, Li D. Hsa-miR-326 targets CCND1 and inhibits nonsmall cell lung cancer development. Oncotarget. 2016; 7:8341-59. doi: 10.18632/oncotarget.7071.
34. Sun CC, Li SJ, Zhang F, Pan JY, Wang L, Yang CL, Xi YY, Li J. Hsa-miR-329 exerts tumor suppressor function through down-regulation of MET in non-small cell lung cancer. Oncotarget. 2016; 7:21510-26. doi: 10.18632/oncotarget.7517.
35. Sun C, Li S, Yang C, Xi Y, Wang L, Zhang F, Li D. MicroRNA-187-3p mitigates non-small cell lung cancer (NSCLC) development through downregulation of BCL6. Biochem Biophys Res Commun. 2016; 471:82-88. doi: 10.1016/j.bbrc.2016.01.175.
36. Barnhill LM, Williams RT, Cohen O, Kim Y, Batova A, Mielke JA, Messer K, Pu M, Bao L, Yu AL, Diccianni MB. High expression of CAI2, a 9p21-embedded long noncoding RNA, contributes to advanced-stage neuroblastoma. Cancer Res. 2014; 74:3753-63. doi: 10.1158/0008-5472.CAN-13-3447.
37. Nie FQ, Zhu Q, Xu TP, Zou YF, Xie M, Sun M, Xia R, Lu KH. Long non-coding RNA MVIH indicates a poor prognosis for non-small cell lung cancer and promotes cell proliferation and invasion. Tumour Biol. 2014; 35:7587-94. doi: 10.1007/s13277-014-2009-7.
38. Yang F, Huo XS, Yuan SX, Zhang L, Zhou WP, Wang F, Sun SH. Repression of the long noncoding RNA-LET by histone deacetylase 3 contributes to hypoxiamediated metastasis. Mol Cell. 2013; 49:1083-96. doi: 10.1016/j.molcel.2013.01.010.
39. Liu YW, Sun M, Xia R, Zhang EB, Liu XH, Zhang ZH, Xu TP, De W, Liu BR, Wang ZX. LincHOTAIR epigenetically silences miR34a by binding to PRC2 to promote the epithelial-to-mesenchymal transition in human gastric cancer. Cell Death Dis. 2015; 6:e1802. doi: 10.1038/cddis.2015.150.
40. Tani H, Torimura M, Akimitsu N. The RNA degradation pathway regulates the function of GAS5 a non-coding RNA in mammalian cells. PLoS One. 2013; 8:e55684. doi: 10.1371/journal.pone.0055684.
41. Kino T, Hurt DE, Ichijo T, Nader N, Chrousos GP. Noncoding RNA gas5 is a growth arrest-and starvation-associated repressor of the glucocorticoid receptor. Sci Signal. 2010; 3:ra8. doi: 10.1126/scisignal.2000568.
42. Ma MZ, Chu BF, Zhang Y, Weng MZ, Qin YY, Gong W, Quan ZW. Long non-coding RNA CCAT1 promotes gallbladder cancer development via negative modulation of miRNA-218-5p. Cell Death Dis. 2015; 6:e1583. doi: 10.1038/cddis.2014.541.
43. Cai M, Wang Z, Zhang J, Zhou H, Jin L, Bai R, Weng Y. Adam17, a Target of Mir-326, Promotes Emt-Induced Cells Invasion in Lung Adenocarcinoma. Cell Physiol Biochem. 2015; 36:1175-85. doi: 10.1159/000430288.
44. Sun C, Huang C, Li S, Yang C, Xi Y, Wang L, Zhang F, Fu Y, Li D. Hsa-miR-326 targets CCND1 and inhibits nonsmall cell lung cancer development. Oncotarget. 2016; 7:8341-59. doi: 10.18632/oncotarget.7071.
45. Wang R, Chen X, Xu T, Xia R, Han L, Chen W, De W, Shu Y. MiR-326 regulates cell proliferation and migration in lung cancer by targeting phox2a and is regulated by HOTAIR. Am J Cancer Res. 2016; 6:173-86.
46. Li J, Li S, Chen Z, Wang J, Chen Y, Xu Z, Jin M, Yu W. miR-326 reverses chemoresistance in human lung adenocarcinoma cells by targeting specificity protein. 1. Tumour Biol. 2016; 37:13287-94. doi: 10.1007/s13277-016-5244-2.
47. Liang Z, Wu H, Xia J, Li Y, Zhang Y, Huang K, Wagar N, Yoon Y, Cho HT, Scala S, Shim H. Involvement of miR-326 in chemotherapy resistance of breast cancer through modulating expression of multidrug resistance-associated protein 1. Biochem Pharmacol. 2010; 79:817-24. doi: 10.1016/j.bcp.2009.10.017.
48. Su BB, Zhou SW, Gan CB, Zhang XN. MiR-330-5p regulates tyrosinase and PDIA3 expression and suppresses cell proliferation and invasion in cutaneous malignant melanoma. J Surg Res. 2016; 203:434-40. doi: 10.1016/j.jss.2016.03.021.
49. Li Y, Zhu X, Xu W, Wang D, Yan J. miR-330 regulates the proliferation of colorectal cancer cells by targeting Cdc42. Biochem Biophys Res Commun. 2013; 431:560-65. doi: 10.1016/j.bbrc.2013.01.016.
50. Qiu S, Lin S, Hu D, Feng Y, Tan Y, Peng Y. Interactions of miR-323/miR-326/miR-329 and miR-130a/miR-155/miR-210 as prognostic indicators for clinical outcome of glioblastoma patients. J Transl Med. 2013; 11:10. doi: 10.1186/1479-5876-11-10.
51. Yao Y, Xue Y, Ma J, Shang C, Wang P, Liu L, Liu W, Li Z, Qu S, Li Z, Liu Y. MiR-330-mediated regulation of SH3GL2 expression enhances malignant behaviors of glioblastoma stem cells by activating ERK and PI3K/AKT signaling pathways. PLoS One. 2014; 9:e95060. doi: 10.1371/journal.pone.0095060.
52. Kim BK, Yoo HI, Choi K, Yoon SK. miR-330-5p inhibits proliferation and migration of keratinocytes by targeting Pdia3 expression. FEBS J. 2015; 282:4692-702. doi: 10.1111/febs.13523.
53. Li J, Li S, Chen Z, Wang J, Chen Y, Xu Z, Jin M, Yu W. miR-326 reverses chemoresistance in human lung adenocarcinoma cells by targeting specificity protein 1. Tumour Biol. 2016; 37:13287-94. doi: 10.1007/s13277-016-5244-2.
54. Wang R, Chen X, Xu T, Xia R, Han L, Chen W, De W, Shu Y. MiR-326 regulates cell proliferation and migration in lung cancer by targeting phox2a and is regulated by HOTAIR. Am J Cancer Res. 2016; 6:173-86.
55. Chen J, Bai M, Ning C, Xie B, Zhang J, Liao H, Xiong J, Tao X, Yan D, Xi X, Chen X, Yu Y, Bast RC, et al. Gankyrin facilitates follicle-stimulating hormonedriven ovarian cancer cell proliferation through the PI3K/AKT/HIF-1a/cyclin D1 pathway. Oncogene. 2016; 35:2506-17. doi: 10.1038/onc.2015.316.
56. Fusté NP, Castelblanco E, Felip I, Santacana M, Fernández-Hernández R, Gatius S, Pedraza N, Pallarés J, Cemeli T, Valls J, Tarres M, Ferrezuelo F, Dolcet X, et al. Characterization of cytoplasmic cyclin D1 as a marker of invasiveness in cancer. Oncotarget. 2016; 7:26979-91. doi: 10.18632/oncotarget.8876.
57. Lee Y, Ko D, Min HJ, Kim SB, Ahn HM, Lee Y, Kim S. TMPRSS4 induces invasion and proliferation of prostate cancer cells through induction of Slug and cyclin D1. Oncotarget. 2016. doi: 10.18632/oncotarget.10382. Epub ahead of print.
58. Marampon F, Gravina G, Ju X, Vetuschi A, Sferra R, Casimiro M, Pompili S, Festuccia C, Colapietro A, Gaudio E, Di Cesare E, Tombolini V, Pestell RG. Cyclin D1 silencing suppresses tumorigenicity, impairs DNA double strand break repair and thus radiosensitizes androgen-independent prostate cancer cells to DNA damage. Oncotarget. 2016; 7:5383-400. doi: 10.18632/oncotarget.6579.
59. Yang P, Chen W, Li X, Eilers G, He Q, Liu L, Wu Y, Wu Y, Yu W, Fletcher JA, Ou WB. Downregulation of cyclin D1 sensitizes cancer cells to MDM2 antagonist Nutlin-3. Oncotarget. 2016; 7:32652-63. doi: 10.18632/oncotarget.8999.
60. Kennedy AL, Vallurupalli M, Chen L, Crompton B, Cowley G, Vazquez F, Weir BA, Tsherniak A, Parasuraman S, Kim S, Alexe G, Stegmaier K. Functional, chemical genomic, and super-enhancer screening identify sensitivity to cyclin D1/CDK4 pathway inhibition in Ewing sarcoma. Oncotarget. 2015; 6:30178-93. doi: 10.18632/oncotarget.4903.
61. Casimiro MC, Di Sante G, Crosariol M, Loro E, Dampier W, Ertel A, Yu Z, Saria EA, Papanikolaou A, Li Z, Wang C, Addya S, Lisanti MP, et al. Kinaseindependent role of cyclin D1 in chromosomal instability and mammary tumorigenesis. Oncotarget. 2015; 6:8525-38. doi: 10.18632/oncotarget.3267.
62. Hwang SJ, Lee HW, Kim HR, Song HJ, Lee DH, Lee H, Shin CH, Joung JG, Kim DH, Joo KM, Kim HH. Overexpression of microRNA-95-3p suppresses brain metastasis of lung adenocarcinoma through downregulation of cyclin D1. Oncotarget. 2015; 6:20434-48. doi: 10.18632/oncotarget.3886.